公开查询

医疗器械登记 ANVISA 数据

按编号、产品、持有人企业或 CNPJ 查询。数据来自 ANVISA 开放数据,每日更新。

47,540 记录

产品注册持有人企业类别有效性
ANTI-SM10300390709VYTTRA DIAGNOSTICOS S.A.II当前有效
ANTI-SM ELISA IgG EA 1593-9601G10338930057EUROIMMUN BRASIL MEDICINA DIAGNOSTICA LTDAII当前有效
ANTI-SS-A ELISA IgG EA 1595-9601 G10338930047EUROIMMUN BRASIL MEDICINA DIAGNOSTICA LTDAII当前有效
ANTI-SSA10300390793VYTTRA DIAGNOSTICOS S.A.II当前有效
ANTI-SSB10300390512VYTTRA DIAGNOSTICOS S.A.II当前有效
ANTI-SSB ELISA IgG EA 1597-9601 G10338930043EUROIMMUN BRASIL MEDICINA DIAGNOSTICA LTDAII当前有效
ANTI-STREPTOLYSIN (O) (ANTI-ESTREPTOLISINA O)10350840034BIOSYS LTDAII当前有效
ANTI-STREPTOLYSIN O STANDARD CONTROL (CONTROLE E PADRAO ASO)10350840041BIOSYS LTDAII当前有效
ANTI-STREPTOLYSIN-O (ASO) STANDARD10303460375IN VITRO DIAGNOSTICA LTDAII当前有效
ANTI-TG10300390596VYTTRA DIAGNOSTICOS S.A.II当前有效
ANTI-TG TEST SYSTEM80048490055USA DIAGNOSTICA LTDAII当前有效
ANTI-THYROGLOBULIN (ANTI-TG)80048490070USA DIAGNOSTICA LTDAII当前有效
ANTI-THYROID PEROXIDASE (ANTI-TPO)80048490078USA DIAGNOSTICA LTDAII当前有效
ANTI-TPO10300390671VYTTRA DIAGNOSTICOS S.A.II当前有效
ANTI-TPO IMMULITE 200010345160829SIEMENS HEALTHCARE DIAGNÓSTICOS LTDAII当前有效
ANTI-TRANSGLUTAMINASE TECIDUAL ELISA IgA EA 1910-9601 A10338930041EUROIMMUN BRASIL MEDICINA DIAGNOSTICA LTDAII当前有效
ANTI-TRANSGLUTAMINASE TECIDUAL IGA10300390516VYTTRA DIAGNOSTICOS S.A.II当前有效
ANTI-nDNA IgG IMUNOFLUORESCENCIA10322610027KIMENZ EQUIPAMENTOS LTDAII当前有效
ANTI-nRNP / Sm ELISA IgG EA 1591-9601 G10338930050EUROIMMUN BRASIL MEDICINA DIAGNOSTICA LTDAII当前有效
ANTI-ssDNA10300390600VYTTRA DIAGNOSTICOS S.A.II当前有效
ANTICARDIOLIPINA ENZIMAIMUNOENSAIO10322610035KIMENZ EQUIPAMENTOS LTDAII当前有效
ANTICARDIOLIPINA G10259610040MEDIVAX INDÚSTRIA E COMÉRCIO LTDAII当前有效
ANTICARDIOLIPINA M10259610041MEDIVAX INDÚSTRIA E COMÉRCIO LTDAII当前有效
ANTICORPO ANTI-ENDOMISIO (AEA)10300390232VYTTRA DIAGNOSTICOS S.A.II当前有效
ANTICORPO ANTI-MITOCONDRIA (AMA)10300390269VYTTRA DIAGNOSTICOS S.A.II当前有效

来源为 ANVISA 医疗健康产品开放数据。该数据提供注册有效期,并不反映完整登记状态;注册可能在到期前已被注销,而此处未显示。决定购买、进口或销售前,请核对 ANVISA 官方查询门户.

接下来的步骤

您的产品需要在巴西注册

HSC 支持医疗器械 ANVISA 注册,从风险分类到申报进度跟踪。

联系专家